Advocates commend Johns Hopkins University for pursuing a public health driven path for sutezolid’s development
TB advocates congratulate Johns Hopkins University’s decision to enter negotiations with the Medicines Patent Pool regarding the licensing of worldwide non-exclusive rights to sutezolid.
In an open letter sent to Johns Hopkins University on May 31, 2016, TB advocates acknowledge and congratulate Johns Hopkins University’s decision to enter negotiations with the Medicines Patent Pool (MPP) regarding the licensing of worldwide non-exclusive rights to sutezolid. Sutezolid is a promising candidate for the treatment of TB.
The letter also commends the university for responding to requests from the TB community to pursue a public health driven path for sutezolid’s development.
“As the first academic institution to contribute to the MPP under its new mandate in TB, Johns Hopkins University is showing important leadership in global health. The inclusion of appropriate terms and conditions in the licensing agreement under negotiation will help to expedite the development of sutezolid, which has been stalled in phase II for several years, by enabling interested researchers and institutions to access and investigate sutezolid as a component of desperately needed novel regimens for TB; and if proven, ensure equitable access for TB patients and treatment providers.”
To read the full letter, click here.
